Gilead Sciences, Inc. with ticker code (GILD) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $109.40 and $66.96 suggesting an average Analsyt target price of $85.47. Given that the stocks previous close was at $78.54 this now indicates there is a potential upside of 8.8%. The 50 day MA is $76.50 and the 200 day MA is $79.22. The company has a market cap of 98.36B. The stock price is currently at: $78.94 USD
The potential market cap would be $107,038,859,746 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.15, revenue per share of $21.87 and a 9.77% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
